Traditionally, the discovery path involves selecting a disease or condition, then inventing a product to address it. NUCRYST Pharmaceuticals has a different approach. NUCRYST identifies noble metals with known therapeutic qualities and uses its platform nanocrystalline technology to create drugs, medical devices, or medical coatings with potentially enhanced therapeutic qualities.
NUCRYST's strategy is to maximize return on investment by partnering with established leaders for effective market penetration of its businesses either through out-licensing or co-development/co-marketing agreements.
NUCRYST completed the first collaboration agreement in 2001 when it licensed its technology for the field of serious wounds to Smith & Nephew, one of the world leaders in advanced wound care management. For additional information on the Smith & Nephew agreement, click here.